Protect All 11 Organ Systems
— Naturally.

Proanthocyanidins (OPCs — Oligomeric Proanthocyanidins) are a class of polyphenolic flavonoids found in plants, particularly concentrated in grape skin and seed. They are the most potent natural antioxidants ever tested, with an ORAC score 50× greater than Vitamin E and 20× greater than Vitamin C. They protect the endothelium — the inner lining of every blood vessel — through multiple simultaneous molecular mechanisms.

Standardisation means the extract is chemically processed to guarantee a minimum concentration of the active compound — in this case, OPCs. >95% standardisation means that at least 95% of every 125mg dose is biologically active proanthocyanidins, with the remaining <5% being inert plant matrix. Compared to the industry-standard 80–85%, Tauphyx delivers 10–15% more active OPCs per dose — verifiable via HPLC (high-performance liquid chromatography) on every batch.

Vitis vinifera is the botanical species name of the European grapevine. Tauphyx uses whole Vitis vinifera grape extract — the exact authenticated species used in all landmark peer-reviewed clinical trials on OPCs. Grape seed extract is a sub-fraction sourced only from grape seeds. The OPC profile and polyphenol composition differs between whole-grape extract and seed-only extract. Tauphyx's sourcing directly matches the extract used in published human RCTs.

OPCs work through 6 simultaneous molecular pathways: (1) eNOS upregulation — increasing nitric oxide production for vasodilation; (2) NF-κB suppression — reducing master inflammatory signalling; (3) ROS neutralisation — direct antioxidant scavenging (50× Vitamin E potency); (4) Collagen cross-linking — strengthening vessel wall structural integrity; (5) Anti-platelet aggregation — reducing microthrombosis risk; (6) BBB penetration — delivering neurological protection. This multi-pathway action explains multi-organ benefits.

HPLC (High-Performance Liquid Chromatography) is the gold-standard analytical method for measuring the exact concentration of specific compounds in a supplement. Tauphyx is HPLC-verified on every single batch — meaning the actual OPC content is scientifically confirmed before the batch is released. Many supplement manufacturers rely on supplier certificates without independent batch verification — HPLC testing on every batch eliminates this uncertainty.

This comparison refers to ORAC (Oxygen Radical Absorbance Capacity) scores — the standardised measure of antioxidant potency. Bagchi D et al. (Free Radical Biology and Medicine) established that Vitis vinifera OPCs demonstrate an ORAC value approximately 50 times greater than alpha-tocopherol (Vitamin E) and 20 times greater than ascorbic acid (Vitamin C) in standardised in vitro testing. This extraordinary potency reflects the unique chemical structure of proanthocyanidin dimers and oligomers.

The endothelium is the single-cell layer lining the inside of every blood vessel in the body. Endothelial dysfunction — failure of these cells to regulate blood flow, inflammation, and clotting — is the common upstream cause of virtually every cardiovascular, renal, retinal, neurological, and metabolic disease. OPCs are the most extensively studied natural compounds for endothelial restoration — which explains why they produce benefits across all 11 organ systems simultaneously.

OPC bioavailability varies by molecular weight. Lower-molecular-weight monomers and dimers are rapidly absorbed (peak plasma levels within 1–2 hours). Higher-molecular-weight oligomers are partially metabolised by gut microbiota into bioavailable phenolic acids. Clinical studies use whole-extract standardised products (matching Tauphyx's formulation) — confirming that the OPC mixture achieves clinically relevant plasma and tissue concentrations at 125mg BD/TDS dosing.

No significant food-OPC interactions are documented in peer-reviewed literature. Tauphyx is best taken after meals for optimal absorption and to minimise any GI sensitivity. Some evidence suggests Vitamin C may enhance OPC absorption by protecting OPCs from oxidation in the GI tract. Avoid taking with milk (may form complexes reducing absorption). Coffee and tea consumption does not meaningfully affect OPC pharmacokinetics at therapeutic doses.

Vitis vinifera OPCs are supported by 500+ peer-reviewed publications and 60+ randomised controlled trials (RCTs) involving over 10,000 patients worldwide. This evidence base spans cardiovascular medicine, neurology, urology, ophthalmology, dermatology, nephrology, hepatology, and immunology — making OPCs one of the most thoroughly studied natural compounds in evidence-based medicine. Key RCTs are linked directly from this page via PubMed DOIs.

Clinical RCTs demonstrate that Vitis vinifera OPCs produce 8–12 mmHg reductions in systolic blood pressure in adults with prehypertension and mild hypertension over 8–12 weeks. This magnitude of reduction is clinically meaningful. Tauphyx is not a substitute for antihypertensive medication. Consult your cardiologist or physician — Tauphyx may be recommended as adjunct nutritional support alongside lifestyle modifications for early or borderline hypertension.

Tauphyx's OPCs improve heart and vascular health through: eNOS upregulation (increases nitric oxide, vasodilates vessels), LDL oxidation inhibition (up to 32% — directly addressing atherogenesis), arterial stiffness reduction (improved endothelial compliance), anti-platelet aggregation (reduces microthrombosis without anticoagulant side effects), and NF-κB suppression (reduces vascular inflammation driving atherosclerosis progression).

OPCs independently lower blood pressure through a different mechanism than pharmaceutical antihypertensives. If combined, there is a potential for additive blood pressure reduction. Consult your cardiologist before starting Tauphyx alongside antihypertensive medications — your physician may wish to monitor your BP more frequently and potentially adjust pharmaceutical doses. Do not start or stop any medication without physician guidance.

OPCs do not directly lower total cholesterol levels. Their key lipid-related benefit is inhibiting LDL oxidation by up to 32% (Bagchi D et al.) — oxidised LDL (oxLDL), not native LDL, is the atherogenic species that drives plaque formation. OPCs also improve HDL functionality and reduce triglycerides as part of metabolic syndrome improvement (Sivaprakasapillai B et al.). Consult your physician if you have clinical hypercholesterolaemia requiring pharmaceutical treatment.

Tauphyx is a dietary supplement and is not intended to treat, cure, or prevent any disease including cardiovascular disease. However, the documented mechanisms — BP reduction, LDL oxidation inhibition, anti-platelet activity, endothelial improvement, and arterial stiffness reduction — are recognised cardiovascular risk factors. Peer-reviewed studies demonstrate that interventions addressing these markers reduce cardiovascular event risk. Your cardiologist can advise on the role of Tauphyx in your specific risk management plan.

Blood pressure reductions in RCTs typically begin appearing at 4–6 weeks of consistent BD/TDS dosing. The most robust cardiovascular outcomes in published RCTs were demonstrated at 8–12 weeks. For structural endothelial improvements (arterial stiffness reduction), a minimum 12-week course is recommended — mirroring RCT duration. Do not stop supplementation prematurely; the benefits are dose-duration dependent.

Yes — metabolic syndrome is one of the most strongly supported indications in the Tauphyx evidence base. Sivaprakasapillai B et al. (Metabolism) demonstrated simultaneous improvement in all 5 metabolic syndrome diagnostic criteria over 16 weeks of OPC supplementation. Consult your physician — Tauphyx may be recommended as part of a comprehensive metabolic syndrome management programme including dietary and lifestyle modifications.

Tauphyx is not indicated for treatment of established heart failure or advanced cardiovascular disease. It is a dietary supplement with demonstrated benefits for early vascular risk reduction. If you have established cardiovascular disease, consult your cardiologist before starting any supplement. Tauphyx may be recommended as adjunct nutritional support at the cardiologist's discretion, but it is not a replacement for established pharmaceutical cardiovascular therapy.

Yes — a 12-week double-blind RCT (Krikorian R et al., Journal of Medicinal Food) demonstrated significant improvements in spatial working memory, verbal recall, and executive function vs. placebo in adults aged 40–70 with subjective memory concerns. The minimum recommended course for cognitive benefits is 12 weeks at the prescribed BD/TDS dose.

The blood-brain barrier (BBB) selectively allows passage of lipid-soluble molecules. OPC dimers and monomers are sufficiently lipid-soluble and small enough to cross the BBB via transcellular passive diffusion and P-glycoprotein-independent transport mechanisms. Once inside the CNS, they accumulate in hippocampal and cortical tissue — the regions most relevant to memory consolidation and cognitive function.

Tauphyx is not indicated for treatment or prevention of Alzheimer's disease or dementia. However, the documented mechanisms — neuroinflammation reduction (NF-κB suppression), cerebral blood flow improvement, oxidative stress reduction in neural tissue, and amyloid-beta aggregation inhibition observed in preclinical studies — are pathways relevant to Alzheimer's pathophysiology. Consult your neurologist. Tauphyx may be considered as preventive nutritional support under medical supervision.

Vitis vinifera OPCs modulate neuroinflammatory pathways and improve cerebral blood flow — two factors associated with mood regulation. Some studies suggest improvements in mood and reduced stress perception with OPC supplementation, potentially related to NF-κB suppression in limbic system tissue. However, Tauphyx is not a treatment for anxiety disorders or depression. Consult a psychiatrist or psychologist for clinical mood disorders.

The Krikorian RCT showing significant cognitive improvements used a 12-week protocol. Some users report subjective improvements in mental clarity and focus within 4–6 weeks, but the most validated cognitive outcomes require a minimum 12-week course at the prescribed BD/TDS dose. Consistent daily dosing is essential — irregular use produces sub-therapeutic plasma OPC concentrations that may not replicate RCT outcomes.

Migraine has significant neurovascular components — arterial vasospasm and trigeminovascular inflammation. OPCs' vasodilatory (eNOS) and anti-inflammatory (NF-κB) mechanisms are mechanistically relevant to migraine pathophysiology. While no large RCTs have specifically studied OPCs for migraine, the cerebral blood flow improvements demonstrated by Edirisinghe I et al. are potentially relevant. Consult your neurologist for migraine management.

Parkinson's disease involves dopaminergic neuron loss driven by oxidative stress and neuroinflammation. OPCs' potent antioxidant activity and neuroinflammation suppression (NF-κB, TNF-α) are mechanistically relevant. However, Tauphyx has not been studied in clinical trials specifically for Parkinson's disease. Consult your neurologist — Tauphyx may be considered as adjunct nutritional support at the physician's discretion, alongside established Parkinson's pharmacotherapy.

The executive function improvements demonstrated in the Krikorian RCT include attention and processing speed components relevant to concentration and focus. OPCs' enhancement of cerebral microvascular perfusion (Edirisinghe I et al.) provides more efficient oxygen and glucose delivery to prefrontal cortical regions responsible for sustained attention, working memory, and executive function. A minimum 12-week course is required for these benefits.

Yes — 6-month double-blind RCTs (Stothers L, Canadian Journal of Urology) demonstrate 40–50% reductions in recurrent UTI episodes among women receiving OPC supplementation vs. placebo. Tauphyx contains the same >95% Vitis vinifera OPC that was tested in these studies. Consult your urologist — Tauphyx is suitable as adjunct preventive nutritional support alongside standard UTI management.

OPCs are not antibacterial — they prevent UTIs through a unique anti-adhesion mechanism. Uropathogenic E. coli (UPEC) use specialised hair-like structures called P-fimbriae to grip uroepithelial cells. OPCs bind to and block these fimbriae — preventing bacteria from attaching to the bladder wall. Without adhesion, UPEC cannot colonise and are flushed out with urination. Since this is a physical blocking mechanism, not an antibiotic one, resistance cannot develop.

Most UTI RCTs with OPCs enrolled women, as women have 10× higher UTI rates due to shorter urethral anatomy. However, the anti-adhesion mechanism is not sex-specific — men with recurrent UTIs, or those with benign prostatic hyperplasia (BPH) causing urinary stasis and UTI susceptibility, may also benefit. Consult your urologist for guidance on Tauphyx in the context of male urinary tract health.

No — Tauphyx is not a treatment for active UTI infections and should not replace antibiotic treatment for established infections. OPCs work as preventive adjunct nutritional support — reducing the likelihood of recurrent UTI episodes through anti-adhesion mechanisms. For an active, symptomatic UTI, antibiotics as prescribed by your physician are the appropriate treatment. Tauphyx may be continued alongside antibiotic treatment as preventive adjunct support.

The Stothers RCT used a 6-month protocol — reflecting that UTI recurrence reduction is measured over longer observation periods. OPC anti-adhesion activity is present from the first dose, but the clinical benefit (fewer UTI episodes) becomes evident over 3–6 months of consistent daily use. The minimum recommended course is 12 weeks, with long-term maintenance use generally recommended under urologist guidance for chronic recurrent UTI sufferers.

Interstitial cystitis involves chronic bladder inflammation with an endothelial/microvascular component. OPCs' NF-κB suppression, mast cell activity reduction, and bladder urothelial protection mechanisms are potentially relevant to IC symptom reduction. Tauphyx has not been specifically studied in clinical trials for IC. Consult your urologist — Tauphyx may be considered as nutritional adjunct support at the physician's discretion.

Kidney stone formation is driven by urinary supersaturation, hypercalciuria, and oxidative stress promoting crystal nucleation. OPCs' antioxidant properties and renal tubular protection mechanisms are potentially relevant, but Tauphyx has not been studied specifically for kidney stone prevention. For established nephrolithiasis management, consult your urologist or nephrologist for evidence-based dietary and pharmaceutical interventions.

The safety of Vitis vinifera OPC supplementation during pregnancy has not been established in clinical trials. Pregnant women have higher UTI susceptibility and risk of complications. Do not take Tauphyx during pregnancy without explicit guidance from your obstetrician or gynaecologist. Your physician will weigh the risk-benefit profile based on your individual clinical situation.

Yes — a 16-week RCT (Sivaprakasapillai B et al., Metabolism) demonstrated simultaneous improvements in all 5 metabolic syndrome diagnostic criteria — waist circumference, fasting glucose, triglycerides, HDL cholesterol, and blood pressure — in participants receiving Vitis vinifera OPC supplementation vs. placebo. Metabolic syndrome is one of the most strongly supported applications in the Tauphyx clinical evidence base.

OPCs improve insulin sensitivity through GLUT-4 transporter upregulation and AMPK pathway activation (Liu H et al., JAFC). The Sivaprakasapillai RCT showed significant reductions in fasting blood glucose in metabolic syndrome patients. Tauphyx is not a diabetes medication and is not intended to replace prescribed diabetes treatments. Consult your endocrinologist or diabetologist — Tauphyx may be considered as adjunct nutritional support in pre-diabetes or early metabolic dysfunction under medical supervision.

The Sivaprakasapillai RCT showed improvements in waist circumference — a key measure of visceral adiposity — with OPC supplementation. OPCs modulate adiponectin (an anti-inflammatory adipokine), AMPK activation, and lipid oxidation pathways that are relevant to metabolic rate and fat metabolism. However, Tauphyx is not a weight-loss supplement. Benefits are metabolic — supporting insulin sensitivity and lipid metabolism. Dietary and lifestyle interventions remain primary for weight management.

OPCs' insulin-sensitising and antioxidant properties are mechanistically relevant to type 2 diabetes management. However, Tauphyx is a dietary supplement, not a diabetes drug. Consult your diabetologist or endocrinologist. If Tauphyx is added to a regimen already including oral hypoglycaemics or insulin, blood glucose should be monitored more closely as additive glucose-lowering effects are possible and pharmaceutical dose adjustments may be required.

PCOS involves insulin resistance, androgen excess, chronic inflammation, and oxidative stress — all pathways where OPCs are active. OPCs' insulin sensitisation, NF-κB inflammatory suppression, and systemic antioxidant activity are mechanistically relevant to PCOS pathophysiology. Tauphyx has not been studied in clinical trials specifically for PCOS. Consult your gynaecologist or endocrinologist — Tauphyx may be considered adjunct support at the physician's discretion.

Tauphyx supports general metabolic and antioxidant function but is not a treatment for hypothyroidism, which requires thyroid hormone replacement under endocrinologist supervision. OPCs' general metabolic support and anti-inflammatory properties may support overall wellbeing in hypothyroid patients, but do not address the hormone deficiency underlying the condition. Consult your endocrinologist.

Yes — the Sivaprakasapillai RCT specifically demonstrated significant triglyceride reductions as one of the 5 metabolic syndrome markers improved with 16 weeks of OPC supplementation. The mechanism involves improved hepatic lipid metabolism and reduced oxidative stress-driven dyslipidaemia. Consult your physician — dietary modification remains primary for hypertriglyceridaemia, with Tauphyx as potential adjunct support.

NAFLD and metabolic syndrome are intimately linked — hepatic insulin resistance and oxidative stress drive both conditions. OPCs' simultaneous metabolic syndrome improvement, hepatic lipid peroxidation reduction, and ALT/AST lowering effects (documented in hepatoprotection studies) make Tauphyx mechanistically relevant to NAFLD management. Consult your hepatologist or gastroenterologist. Tauphyx may be recommended as adjunct nutritional support alongside dietary modifications under physician supervision.

Yamakoshi J et al. demonstrated that Vitis vinifera OPCs protect retinal pigment epithelial (RPE) cells from light-induced and oxidative stress damage — the primary cellular mechanism in AMD progression. OPCs' potent antioxidant activity addresses the choroidal oxidative stress driving drusen formation and RPE atrophy in AMD. Tauphyx is not a treatment for established AMD — consult your ophthalmologist for AMD management and to determine whether Tauphyx is appropriate as preventive nutritional adjunct support.

Yes — Ohguro H et al. (Journal of Ocular Pharmacology) demonstrated significant reduction in digital eye strain symptoms and improved accommodation recovery time with OPC supplementation vs. placebo. This is particularly relevant for screen-heavy professionals, students, and anyone experiencing asthenopia (eye fatigue). A minimum 12-week course is recommended for consistent benefit.

Diabetic retinopathy involves progressive retinal microvasculature damage driven by hyperglycaemia-induced oxidative stress — precisely the pathway OPCs counter. OPCs' glomerular and endothelial protection mechanisms are equally applicable to retinal capillaries. Tauphyx is not a treatment for diabetic retinopathy. Consult your ophthalmologist and diabetologist — Tauphyx may be considered adjunct nutritional support under medical supervision for diabetic patients with early retinopathy risk.

Clinical studies (Ohguro H et al.) demonstrated improvements in contrast sensitivity with OPC supplementation — a visual function directly relevant to night driving, low-light reading, and spatial detail perception. The mechanism involves enhanced retinal microvascular perfusion and RPE cell function. A 12-week course at BD/TDS dose was used in studies showing these benefits.

Glaucoma involves optic nerve damage driven by elevated intraocular pressure and vascular risk factors. OPCs' neuroprotective properties and microvascular integrity support are mechanistically relevant but Tauphyx has not been studied specifically for glaucoma in clinical trials. Consult your ophthalmologist — Tauphyx may be considered adjunct nutritional support at the specialist's discretion, but does not replace IOP-lowering pharmaceutical treatment for established glaucoma.

There are no contraindications between Tauphyx supplementation and contact lens wear. OPCs work systemically through oral supplementation and do not interact with external eye surfaces or lens materials. Tauphyx's dry eye and eye strain benefits (improved microvascular perfusion and reduced ocular inflammation) may be particularly relevant for prolonged contact lens wearers who experience discomfort. Consult your optometrist or ophthalmologist.

OPCs protect glomerular microvasculature — the specialised capillary network in kidneys responsible for blood filtration. Studies demonstrate reduction in oxidative stress-induced nephropathy, improved eGFR markers, and creatinine stabilisation in at-risk populations. Tauphyx is not a kidney disease treatment — consult your nephrologist for kidney disease management and to determine whether Tauphyx is appropriate as adjunct nutritional support.

CKD involves progressive glomerular and tubular damage driven by oxidative stress, inflammation, and microvascular injury — all pathways where OPCs have demonstrated protective activity. Tauphyx is not a CKD treatment. However, consult your nephrologist — Tauphyx may be considered as adjunct nutritional support in early-stage CKD patients, particularly those with diabetic or hypertensive nephropathy aetiology, at the specialist's discretion.

OPCs are primarily metabolised by gut microbiota and liver, with urinary excretion of phenolic acid metabolites. In patients with significantly reduced kidney function (eGFR <30), metabolite accumulation is theoretically possible. Consult your nephrologist before starting Tauphyx if you have CKD or reduced kidney function. Your specialist can assess the risk-benefit profile based on your specific kidney function parameters.

Diabetic nephropathy is the leading cause of end-stage renal disease in India. The progression involves glomerular oxidative stress, mesangial expansion, and podocyte loss — all pathways where Vitis vinifera OPCs have demonstrated protective activity in peer-reviewed studies. Tauphyx's combined metabolic (glucose-lowering) and renal (glomerular oxidative stress reduction) mechanisms make it particularly relevant as adjunct nutritional support for diabetic patients under nephrologist supervision.

No significant effects of OPC supplementation on electrolyte balance have been reported in peer-reviewed literature at the 125mg BD/TDS dose. OPCs do not have diuretic, natriuretic, or electrolyte-altering mechanisms. Patients on kidney disease diets with potassium or phosphate restrictions can discuss Tauphyx supplementation with their nephrologist — the supplement itself contains no significant mineral content.

Proteinuria indicates glomerular filtration membrane damage — allowing albumin to leak into urine. OPCs' protective effects on glomerular capillary endothelium and filtration membrane integrity are mechanistically relevant to reducing proteinuria. Studies in diabetic nephropathy models show proteinuria reduction with OPC supplementation. Consult your nephrologist — established proteinuria requires medical evaluation and management beyond nutritional supplementation.

Yes — Vitis vinifera OPCs stimulate collagen synthesis, inhibit collagen-degrading MMP enzymes, reduce UV-induced lipid peroxidation, and improve skin microvascular perfusion. Studies (Yamakoshi J et al., Sato M et al.) demonstrate improved skin elasticity, reduced wrinkle depth, and improved wound healing with OPC supplementation. A minimum 12-week course at BD dose is required for skin structure benefits to manifest — collagen remodelling is a slow biological process.

OPCs inhibit tyrosinase — the rate-limiting enzyme in melanin synthesis — reducing pigmentation accumulation in melanocytes. This mechanism is relevant to melasma, post-inflammatory hyperpigmentation (PIH), sun spots, and UV-induced tanning. Sato M et al. demonstrated reduced dermal melanin with OPC supplementation over 12 weeks. Results require consistent 12-week minimum use. Consult your dermatologist for comprehensive melasma management including topical treatments and sun protection.

Acne involves sebaceous follicle inflammation driven by P. acnes bacteria, androgen stimulation, and oxidative stress in sebocytes. OPCs' potent anti-inflammatory (NF-κB suppression) and antioxidant mechanisms reduce oxidative damage in sebaceous tissue. While no dedicated acne RCTs have been conducted with OPCs, the anti-inflammatory mechanisms are relevant. Consult your dermatologist for acne management alongside Tauphyx supplementation as potential adjunct support.

OPCs accelerate wound healing through two mechanisms: (1) Improved wound bed microvascular perfusion (eNOS upregulation → nitric oxide → angiogenesis and tissue perfusion), and (2) Collagen synthesis stimulation at wound margins. These mechanisms are relevant to post-surgical recovery, diabetic wound healing, and chronic ulcer management. Consult your surgeon or physician about Tauphyx as nutritional adjunct support during recovery.

Eczema and psoriasis involve Th2/Th17 immune dysregulation and barrier dysfunction. OPCs' immunomodulatory properties (Th1/Th2 balance) and NF-κB suppression are mechanistically relevant. However, Tauphyx has not been studied specifically for atopic dermatitis or psoriasis in clinical trials. Consult your dermatologist — Tauphyx may be considered as adjunct nutritional support at the specialist's discretion alongside established dermatological treatments.

Skin structural improvements (collagen remodelling, elasticity) require a minimum 12 weeks of consistent daily use — matching published study durations. Pigmentation reduction (tyrosinase inhibition) begins to manifest at 8–12 weeks. Subjective skin quality improvements (hydration, radiance from improved microvasculature) may be noticed earlier — at 4–6 weeks. Always use daily SPF protection alongside Tauphyx supplementation for optimal skin health outcomes.

OPCs inhibit COX-2 inflammatory pathways in synovial tissue — the same enzyme targeted by NSAIDs like ibuprofen and celecoxib — without the gastrointestinal or cardiovascular risks of pharmaceutical COX-2 inhibitors. OPCs also cross-link cartilage collagen and inhibit MMP-13 (the primary cartilage-degrading enzyme in osteoarthritis). Grimm T et al. and Ferretti G et al. demonstrated anti-inflammatory and chondroprotective effects. Consult your rheumatologist or orthopaedic specialist.

OPCs protect osteoblasts (bone-building cells) from reactive oxygen species that promote osteoclast-mediated bone resorption. By restoring the osteoblast/osteoclast balance, OPCs support healthy bone mineral density maintenance. This is particularly relevant for post-menopausal women with elevated osteoporosis risk. Tauphyx is not a replacement for established osteoporosis treatments (calcium, Vitamin D, bisphosphonates). Consult your orthopaedic physician or gynaecologist.

OPCs have independent COX-2 inhibitory activity. Adding Tauphyx to NSAID therapy may produce additive anti-inflammatory effects — which could be beneficial but should be monitored by your physician. Consult your rheumatologist or orthopaedic specialist before combining Tauphyx with NSAIDs. Over time, if Tauphyx provides adequate joint pain relief, your physician may consider reducing NSAID doses — reducing long-term NSAID-related GI and cardiovascular risks.

Gout involves uric acid crystal deposition in joints and acute inflammatory arthritis episodes. OPCs' anti-inflammatory (NF-κB, COX-2) mechanisms are relevant to reducing the inflammatory cascade during gout flares. Some evidence suggests OPCs may modestly reduce uric acid levels through improved renal tubular urate excretion. Consult your physician — Tauphyx is not a urate-lowering agent and does not replace allopurinol or other established gout treatments.

Exercise-induced muscle damage involves oxidative stress, micro-inflammation, and delayed-onset muscle soreness (DOMS) — all pathways where OPCs are active. Some studies suggest OPC supplementation reduces exercise-induced oxidative biomarkers and may accelerate muscle recovery. Athletes and fitness enthusiasts may benefit from Tauphyx's systemic anti-inflammatory and antioxidant mechanisms as part of recovery nutrition. Minimum 12-week course is recommended for consistent benefit.

Tendons and ligaments are composed predominantly of Type I collagen. OPCs' collagen cross-linking, MMP inhibition, and anti-inflammatory properties directly support tendon structural integrity and repair. OPC supplementation has shown accelerated tendon healing in animal models. Consult your orthopaedic physician or physiotherapist about Tauphyx as nutritional adjunct support during tendon rehabilitation alongside appropriate physical therapy.

OPCs modulate immune function rather than simply "boosting" it. They suppress overactive inflammatory immune responses (NF-κB, TNF-α) while supporting NK cell activity and Th1/Th2 immune balance. This immunomodulatory profile is more clinically beneficial than simple immune stimulation — particularly for individuals with chronic inflammatory conditions or autoimmune predisposition. The net effect is a more balanced, regulated immune response with reduced systemic inflammatory burden.

Yes — Broncel M et al. (European Journal of Nutrition) demonstrated significant reductions in high-sensitivity C-reactive protein (hsCRP) after 8 weeks of standardised OPC supplementation. hsCRP is the primary blood biomarker of systemic low-grade inflammation — elevated levels correlate with cardiovascular risk, metabolic dysfunction, and accelerated ageing. Normalising hsCRP through OPC supplementation represents a meaningful improvement in systemic inflammatory burden.

OPCs' immunomodulatory properties (NF-κB suppression, Th1/Th2 balance) are mechanistically relevant to autoimmune conditions — but effects vary by condition and individual immune profile. Do not use Tauphyx as a substitute for immunosuppressant therapy for confirmed autoimmune diseases. Consult your rheumatologist or immunologist — Tauphyx may be considered as adjunct nutritional support at the specialist's discretion for select autoimmune contexts.

OPCs modulate Th2 immunity — the arm overactivated in allergic conditions (hay fever, food allergies, atopic dermatitis, allergic asthma). Their NF-κB and histamine-related inflammatory suppression may reduce allergic response intensity. Tauphyx is not an antihistamine and should not replace antiallergic medications during acute allergic reactions. Consult your allergist or immunologist about Tauphyx as potential adjunct support for atopic conditions.

Post-COVID (long COVID) involves persistent microvascular inflammation, endothelial dysfunction, oxidative stress, and neuroinflammation — all pathways where OPCs have demonstrated activity. OPCs' multi-organ endothelial protection and systemic anti-inflammatory mechanisms are mechanistically relevant to long COVID's vascular pathophysiology. Consult your physician — Tauphyx may be considered as nutritional adjunct support for post-COVID recovery at the doctor's discretion.

Chronic fatigue has multi-factorial aetiology — including mitochondrial dysfunction, neuroinflammation, and endothelial microvascular insufficiency limiting tissue oxygenation. OPCs address neuroinflammatory (NF-κB, BBB-penetrating) and vascular (eNOS, microvascular perfusion) components of fatigue pathophysiology. Some clinical trial participants in OPC studies have reported improvements in energy levels and general wellbeing. Consult your physician for evaluation of chronic fatigue aetiology before starting supplementation.

Yes — Vitis vinifera OPCs are among the most evidence-backed natural hepatoprotectants for NAFLD. Multiple studies demonstrate reductions in ALT and AST liver enzymes, inhibition of hepatic lipid peroxidation, and protection against hepatocellular oxidative damage in NAFLD models. OPCs' 50× Vitamin E antioxidant potency directly neutralises the ROS species responsible for hepatic lipid peroxidation progression from simple steatosis to NASH. Consult your hepatologist or gastroenterologist for personalised guidance — Tauphyx may be recommended as adjunct nutritional support alongside dietary modifications.

Elevated ALT and AST are markers of hepatocellular inflammation and damage. Studies in NAFLD and drug-induced liver injury models demonstrate that Vitis vinifera OPCs significantly reduce ALT and AST elevations — indicating reduced hepatocyte damage. Consult your physician if you have abnormal liver function tests — elevated ALT/AST requires medical evaluation to identify the underlying cause. Tauphyx may be considered adjunct nutritional support under hepatologist supervision, not a liver disease treatment.

Alcohol metabolism generates acetaldehyde and ROS species that cause direct oxidative hepatocellular damage. OPCs' extraordinary antioxidant potency (50× Vitamin E) neutralises these reactive species in hepatic tissue. Preclinical and some clinical studies demonstrate hepatoprotective effects of grape-derived OPCs against alcohol-induced liver damage. Tauphyx is not a treatment for alcoholic liver disease — alcohol cessation remains the primary intervention. Consult your physician. Tauphyx should not be used as a justification to continue alcohol consumption.

COPD involves progressive airway inflammation, alveolar destruction, and oxidative stress — pathways where OPCs are mechanistically active. OPCs suppress NF-κB-mediated airway cytokine cascades (IL-6, IL-8, TNF-α), protect alveolar capillary endothelium, and neutralise oxidative damage from cigarette smoke and air pollutants. Tauphyx is not a bronchodilator or COPD medication — consult your pulmonologist. It may be considered as adjunct nutritional support alongside established COPD pharmacotherapy, not a replacement.

Asthma and allergic bronchitis involve Th2-driven mast cell activation, eosinophilic airway inflammation, and bronchial hyperresponsiveness. OPCs modulate Th1/Th2 immune balance, reduce NF-κB-mediated airway inflammation, and inhibit mast cell degranulation in preclinical models. Tauphyx is not an asthma reliever or controller medication — do not use it in place of prescribed inhalers or bronchodilators. Consult your pulmonologist or allergist about Tauphyx as potential adjunct nutritional support.

Yes — this is one of the most relevant applications for urban Indians. India's major cities consistently record some of the highest PM2.5 and PM10 levels globally. Airborne particulate matter generates massive pulmonary oxidative stress and NF-κB-driven inflammation in bronchial epithelium and alveolar capillaries. OPCs' systemic antioxidant activity (50× Vitamin E) and NF-κB suppression directly counter pollution-induced pulmonary oxidative damage. A minimum 12-week course at BD/TDS dose is recommended for consistent pulmonary endothelial protection.

125mg (one vegetarian capsule) twice daily (BD) or three times daily (TDS) as directed by your healthcare expert. Best taken after meals — breakfast and dinner for BD dosing; breakfast, lunch, and dinner for TDS dosing — with 200ml of water. Do not exceed the dose recommended by your physician. The dose used in clinical studies showing multi-organ benefits was 125mg BD (250mg/day) to 125mg TDS (375mg/day).

The minimum recommended course for Tauphyx is 12 weeks (approximately 3 months) — directly mirroring the protocols used in randomised controlled trials that demonstrated cardiovascular, cognitive, urinary, metabolic, and multi-organ benefits. Clinical studies show measurable biomarker improvements within 4–8 weeks, with full and robust benefits emerging at 12+ weeks of consistent BD/TDS dosing. A 12-week course = 2–3 bottles depending on prescribed dosing frequency.

The maximum duration and dose of Tauphyx is as directed by your doctor. Do not exceed the dose recommended by your healthcare expert. For most individuals, this is 125mg BD or TDS. Long-term use at physician-recommended doses is generally safe based on the available safety literature. Your physician will determine the appropriate dose and duration based on your clinical indication, health status, and concurrent medications.

If you miss a dose, take it as soon as you remember — unless it is almost time for your next scheduled dose, in which case skip the missed dose and resume your regular schedule. Do not double up to make up for a missed dose. Consistent daily dosing is important for maintaining therapeutic plasma OPC concentrations. Missing occasional doses during a 12-week course is unlikely to significantly impair outcomes, but consistent daily use produces the best results.

Yes — take Tauphyx after meals for two reasons: (1) Food-induced gastric acid changes and lipid-emulsification improve OPC absorption bioavailability; (2) Taking with food minimises any potential GI sensitivity in individuals with sensitive stomachs. The meal need not be large — a light snack is sufficient. Avoid taking on a completely empty stomach.

Take Tauphyx with plain water (200ml recommended). Avoid milk — the casein proteins in milk may bind to polyphenols and reduce OPC absorption. Citrus juices (orange, lemon) containing Vitamin C may actually enhance OPC absorption by protecting them from oxidation in the GI tract. Avoid black tea or coffee immediately after — tannins may complex with OPCs and reduce absorption.

Tauphyx is formulated for adults (18+). Do not administer to children without paediatric physician guidance. For elderly individuals, the standard 125mg BD dose is generally appropriate — no dose reduction is required based on age alone. Elderly individuals on multiple medications should consult their physician before starting Tauphyx to review potential interactions. The vegetarian capsule can be opened and the powder mixed with food if capsule swallowing is difficult — consult your physician.

No evidence of adverse effects of OPC supplementation during menstruation has been reported in clinical literature. OPCs have mild anti-platelet activity — theoretical concern exists about excessive menstrual bleeding in individuals with heavy periods combined with anticoagulant use. If you have menorrhagia (heavy periods) or are on blood thinners, consult your gynaecologist before starting Tauphyx.

Tauphyx should ideally be taken after a meal for optimal absorption. If intermittent fasting restricts eating to certain windows, take Tauphyx immediately after breaking your fast or with your first meal of the day. Do not take Tauphyx while in a complete fasting state (no food at all) — take it with or immediately after a meal within your eating window. The supplement contains negligible caloric content (0.8 Kcal per capsule).

For BD dosing: after breakfast and after dinner. For TDS dosing: after breakfast, after lunch, and after dinner. Spacing doses evenly through the day maintains more consistent plasma OPC concentrations compared to taking multiple doses at once. There is no significant pharmacokinetic advantage to morning vs. evening dosing — consistency of timing matters more than specific time of day.

OPCs are generally very well tolerated. Reported adverse events are rare and typically mild (occasional loose stools at very high doses, which do not occur at 125mg BD/TDS). If you experience any unusual symptoms after starting Tauphyx — GI discomfort, skin reaction, unusual bleeding — stop taking the supplement and consult your physician immediately. Contact GoIntegrity via WhatsApp (+91-8800934611) or email (info@gointegrity.in) to report any adverse experience. Physician evaluation is always the appropriate first step.

The safety of Vitis vinifera OPC supplementation during pregnancy and breastfeeding has not been established in clinical trials. Do not take Tauphyx during pregnancy or while breastfeeding without explicit guidance from your obstetrician or gynaecologist. Your physician will assess the risk-benefit profile based on your individual clinical situation and health status. This precaution is standard for all dietary supplements in pregnancy.